Target intelligence / Profile preview

Tyrosine-protein kinase Mer (MerTK) (MERTK)

Target
MERTK
Molecular classification
Receptor tyrosine kinase (RTK), TAM family receptor (Tyro3–Axl–Mer), Enzyme (protein kinase), Receptor
01

Overview

MerTK is a receptor tyrosine kinase of the TAM family (Tyro3–Axl–Mer) that transduces signals from ligands such as Gas6 and Protein S to regulate efferocytosis, immune homeostasis, and cell survival pathways including PI3K/AKT and MAPK. Its extracellular region includes two immunoglobulin-like domains and two fibronectin type III domains, followed by a single-pass transmembrane segment and an intracellular tyrosine kinase domain; proteolytic cleavage generates a soluble Mer that can act as a decoy receptor. Ligand binding induces receptor autophosphorylation and recruitment of adaptors (e.g., GRB2, PLCG2), promoting processes such as macrophage clearance of apoptotic cells, platelet aggregation, and cytoskeletal reorganization; in retinal pigment epithelium it mediates phagocytosis of rod outer segments. MerTK functions as an innate immune checkpoint in macrophages, dampening TLR-driven inflammation via STAT1-dependent induction of SOCS1/3, and is a therapeutic target in cancer; structural studies of its kinase domain support development of small-molecule inhibitors that stabilize inactive conformations or engage the activation loop (type I/1.5).

Other names
MerMer receptor tyrosine kinaseReceptor tyrosine kinase MerTKProto-oncogene c-MerMERMER proto-oncogene, tyrosine kinaseRTK MerTyro3/Axl/Mer family receptor
02

Mechanism of action

Small-molecule kinase inhibitors targeting the ATP-binding site/kinase domain of MerTK to block autophosphorylation and downstream signaling (Type I/1.5; inactive-state stabilization reported); Inhibition of MerTK to relieve innate immune checkpoint activity in macrophages, enhancing anti-tumor immunity

03

Biological functions

Efferocytosis (phagocytosis of apoptotic cells) and apoptotic cell tethering/internalizationInnate immune checkpoint signaling and suppression of TLR-mediated responses via SOCS1/3 inductionCell survival, migration, differentiation signaling (e.g., PI3K/AKT, MAPK)Platelet aggregation and cytoskeleton reorganizationRetinal pigment epithelium phagocytosis of rod outer segmentsRegulation of dendritic cell activation and BAFF secretion (negative regulation of DC function)
04

Disease associations

Cancer (tumor immune evasion; target in cancer immunotherapy)Autoimmunity/Inflammation (loss of MerTK linked to dysregulated DCs and autoantibodies)Retinal degeneration when dysfunctional (RPE phagocytosis role implies retinal disease involvement)Thrombosis/hematologic processes (platelet aggregation role)
05

Safety considerations

Risk of autoimmunity or excessive inflammation when inhibiting an innate immune checkpoint (MerTK restrains TLR signaling and DC activation)Potential effects on retinal homeostasis (RPE phagocytosis) with prolonged systemic inhibitionEffects on hemostasis/platelet function due to role in platelet aggregation
06

Interacting drugs

Cabozantinib

5 more in the full profile.

07

Biomarkers

MERTK expression (tumor-associated macrophages, myeloid cells) as a potential selection marker for MerTK inhibitor or checkpoint strategiesSoluble Mer (shed ectodomain) as a decoy/indicator of receptor cleavage and pathway activity

Beyond the preview

Go deeper on Tyrosine-protein kinase Mer (MerTK) (MERTK).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tyrosine-protein kinase Mer (MerTK) (MERTK).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call